Literature DB >> 24222104

State of the art in the treatment of laryngeal cancer.

Friederike Jenckel1, Rainald Knecht.   

Abstract

Nowadays clinics can offer patients a variety of different therapy options when laryngeal squamous cell carcinoma is diagnosed histologically. Depending on a variety of different factors, including tumor size, possible metastasis, health status and age of the patient, but also economic factors, a treatment schedule is established. Aim of every treatment decision should be organ larynx preservation and preservation of laryngeal function. The objective of this review is to give an overview of treatment modalities for laryngeal cancer, based not only on traditional but also on the latest studies regarding the treatment of this disease. Surgical approaches, as well as conservative treatment options, such as chemoradiotherapy, induction therapy and target therapy, are discussed. The optimal combination of surgical treatment and conservative treatment modalities need to be further investigated. Furthermore optimal laryngeal function as well as laryngeal preservation must be re-defined.

Entities:  

Keywords:  Laryngeal cancer; larynx preservation; organ-preservating surgery; radiochemotherapy

Mesh:

Year:  2013        PMID: 24222104

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Integrated rehabilitation after total laryngectomy: a pilot trial study.

Authors:  Ylenia Longobardi; Vezio Savoia; Francesco Bussu; Luciana Morra; Giorgia Mari; Domenico A Nesci; Claudio Parrilla; Lucia D'Alatri
Journal:  Support Care Cancer       Date:  2019-01-26       Impact factor: 3.603

2.  Different spectral hounsfield unit curve and high-energy virtual monochromatic image characteristics of squamous cell carcinoma compared with nonossified thyroid cartilage.

Authors:  R Forghani; M Levental; R Gupta; S Lam; N Dadfar; H D Curtin
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-05       Impact factor: 3.825

3.  Diagnostic accuracy of surface coil MRI in assessing cartilaginous invasion in laryngeal tumours: Do we need contrast-agent administration?

Authors:  Lorenzo Preda; Giorgio Conte; Luke Bonello; Caterina Giannitto; Elena Tagliabue; Sara Raimondi; Mohssen Ansarin; Luigi De Benedetto; Augusto Cattaneo; Fausto Maffini; Massimo Bellomi
Journal:  Eur Radiol       Date:  2017-05-05       Impact factor: 5.315

4.  miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma.

Authors:  Changhui Gao; Shousen Hu
Journal:  Cancer Biol Ther       Date:  2019-03-25       Impact factor: 4.742

5.  Serum-derived extracellular vesicles mediate Smad4 expression through shuttling microRNA-27a in the progression of laryngeal squamous cell carcinoma.

Authors:  Yu Shuang; Xiaofeng Yao; Jing Liu; Juntao Niu; Wenyu Guo; Chao Li
Journal:  Hum Cell       Date:  2022-05-12       Impact factor: 4.174

Review 6.  MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy.

Authors:  Pei Li; Hui Liu; Zhiyuan Wang; Feng He; Haifeng Wang; Zhi Shi; Ankui Yang; Jin Ye
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

Review 7.  The role of microRNAs expression in laryngeal cancer.

Authors:  Xin Yu; Zheng Li
Journal:  Oncotarget       Date:  2015-09-15

Review 8.  Evidence and evidence gaps of laryngeal cancer surgery.

Authors:  Susanne Wiegand
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

9.  Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells.

Authors:  Aneta Grabarska; Jarogniew J Łuszczki; Ewa Nowosadzka; Ewelina Gumbarewicz; Witold Jeleniewicz; Magdalena Dmoszyńska-Graniczka; Krystyna Kowalczuk; Krzysztof Kupisz; Krzysztof Polberg; Andrzej Stepulak
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

10.  Tumor Volumes and Prognosis in Laryngeal Cancer.

Authors:  Mohamad R Issa; Stuart E Samuels; Emily Bellile; Firas L Shalabi; Avraham Eisbruch; Gregory Wolf
Journal:  Cancers (Basel)       Date:  2015-11-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.